Quotient - QTNT Stock Forecast, Price & News

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Quotient Stock Performance

Quotient stock remained flat at $0.24 during midday trading on Wednesday. The company had a trading volume of 1,706,517 shares, compared to its average volume of 1,393,519. The business has a 50-day simple moving average of $0.30 and a 200-day simple moving average of $0.75. Quotient has a 12 month low of $0.23 and a 12 month high of $3.43. The firm has a market capitalization of $24.37 million, a price-to-earnings ratio of -0.20 and a beta of 2.74.

Quotient (NASDAQ:QTNT - Get Rating) last announced its earnings results on Friday, June 24th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.09. During the same period in the previous year, the firm earned ($0.39) EPS. On average, analysts expect that Quotient will post -0.66 EPS for the current year.

Wall Street Analyst Weigh In

QTNT has been the subject of several analyst reports. Cowen dropped their target price on Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a report on Wednesday, June 29th. BTIG Research lowered their price target on Quotient from $9.00 to $1.50 and set a "buy" rating for the company in a report on Wednesday, June 29th. StockNews.com assumed coverage on Quotient in a report on Monday. They set a "hold" rating for the company. Cowen lowered their price target on Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a report on Wednesday, June 29th. Finally, The Goldman Sachs Group lowered their price target on Quotient from $3.00 to $1.50 and set a "neutral" rating for the company in a report on Tuesday, April 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Quotient currently has an average rating of "Moderate Buy" and an average price target of $2.25.

Insider Activity at Quotient

In other news, Director Zubeen Shroff bought 4,666,666 shares of the stock in a transaction that occurred on Friday, June 24th. The stock was bought at an average cost of $0.30 per share, for a total transaction of $1,399,999.80. Following the acquisition, the director now directly owns 11,995,740 shares of the company's stock, valued at approximately $3,598,722. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 4,818,140 shares of company stock worth $1,440,354 in the last three months. 10.50% of the stock is owned by company insiders.